112 related articles for article (PubMed ID: 29442000)
1. MicroRNA-132 sensitizes nasopharyngeal carcinoma cells to cisplatin through regulation of forkhead box A1 protein.
Li YL; Zhao YG; Chen B; Li XF
Pharmazie; 2016 Dec; 71(12):715-718. PubMed ID: 29442000
[TBL] [Abstract][Full Text] [Related]
2. microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2.
Yuan TZ; Zhang HH; Lin XL; Yu JX; Yang QX; Liang Y; Deng J; Huang LJ; Zhang XP
Mol Med Rep; 2017 Apr; 15(4):2223-2228. PubMed ID: 28260044
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1.
Cheng D; Xu Y; Sun C; He Z
Mol Cell Biochem; 2016 Dec; 423(1-2):85-91. PubMed ID: 27686452
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells.
Liu Z; Liu J; Li L; Nie D; Tao Q; Wu J; Fan J; Lin C; Zhao S; Ju D
PLoS One; 2015; 10(8):e0135236. PubMed ID: 26288183
[TBL] [Abstract][Full Text] [Related]
5. BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer.
Kuang CM; Fu X; Hua YJ; Shuai WD; Ye ZH; Li Y; Peng QH; Li YZ; Chen S; Qian CN; Huang W; Liu RY
Cell Death Dis; 2017 Jun; 8(6):e2874. PubMed ID: 28617432
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of GRP78 enhances cell death by cisplatin and radiotherapy in nasopharyngeal cells.
Huang YY; Pu LJ; Song LL; Ma LY; Liu H; Jiang CC
Anticancer Drugs; 2016 Sep; 27(8):726-33. PubMed ID: 27254284
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.
Zhang P; Liu H; Xia F; Zhang QW; Zhang YY; Zhao Q; Chao ZH; Jiang ZW; Jiang CC
Int J Mol Med; 2014 Jan; 33(1):151-9. PubMed ID: 24173500
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
9. miR-1278 sensitizes nasopharyngeal carcinoma cells to cisplatin and suppresses autophagy via targeting ATG2B.
Zhao Y; Wang P; Wu Q
Mol Cell Probes; 2020 Oct; 53():101597. PubMed ID: 32407879
[TBL] [Abstract][Full Text] [Related]
10. Identification Keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines.
Tang S; Huang W; Zhong M; Yin L; Jiang H; Hou S; Gan P; Yuan Y
J Proteomics; 2012 Apr; 75(8):2352-60. PubMed ID: 22348822
[TBL] [Abstract][Full Text] [Related]
11. FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.
Song Y; Zhou X; Bai W; Ma X
Tumour Biol; 2015 Jun; 36(6):4197-202. PubMed ID: 25586348
[TBL] [Abstract][Full Text] [Related]
12. Has‑miR‑125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53‑dependent manner by targeting p53 mRNA.
Chen JJ; Liu SX; Chen MZ; Zhao ZY
Mol Med Rep; 2015 Sep; 12(3):3569-3574. PubMed ID: 26017674
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin.
Xie SM; Fang WY; Liu Z; Wang SX; Li X; Liu TF; Xie WB; Yao KT
J Transl Med; 2008 Oct; 6():55. PubMed ID: 18834541
[TBL] [Abstract][Full Text] [Related]
14. miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin.
Zhen Y; Fang W; Zhao M; Luo R; Liu Y; Fu Q; Chen Y; Cheng C; Zhang Y; Liu Z
Oncogene; 2017 Jan; 36(2):275-285. PubMed ID: 27270423
[TBL] [Abstract][Full Text] [Related]
15. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
Chan KC; Chan LS; Ip JC; Lo C; Yip TT; Ngan RK; Wong RN; Lo KW; Ng WT; Lee AW; Tsao GS; Kahn M; Lung ML; Mak NK
Sci Rep; 2015 Apr; 5():9979. PubMed ID: 25897700
[TBL] [Abstract][Full Text] [Related]
17. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
18. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
Wang SS; Guan ZZ; Xiang YQ; Jiang WQ; Lin TY; Zhang L
Ai Zheng; 2004 Nov; 23(11 Suppl):1365-9. PubMed ID: 15566638
[TBL] [Abstract][Full Text] [Related]
19. ARC is highly expressed in nasopharyngeal carcinoma and confers X-radiation and cisplatin resistance.
Wu P; Tang Y; He J; Qi L; Jiang W; Zhao S
Oncol Rep; 2013 Oct; 30(4):1807-13. PubMed ID: 23877130
[TBL] [Abstract][Full Text] [Related]
20. EBV-encoded LMP-1 sensitizes nasopharyngeal carcinoma cells to genotoxic drugs by down-regulating Cabin1 expression.
Chang PY; Wu ZZ; Sun NK; Chao CC
J Cell Physiol; 2014 Mar; 229(3):309-22. PubMed ID: 23939952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
